
Noble E. Jarrell
Examiner (ID: 14167, Phone: (571)272-9077 , Office: P/1625 )
| Most Active Art Unit | 1699 |
| Art Unit(s) | 1625, 1699, 1622, 1624, 1609 |
| Total Applications | 1419 |
| Issued Applications | 950 |
| Pending Applications | 180 |
| Abandoned Applications | 334 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17713465
[patent_doc_number] => 11377448
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-05
[patent_title] => Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid
[patent_app_type] => utility
[patent_app_number] => 16/499732
[patent_app_country] => US
[patent_app_date] => 2018-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 4397
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16499732
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/499732 | Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid | Mar 27, 2018 | Issued |
Array
(
[id] => 15948745
[patent_doc_number] => 10662261
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-05-26
[patent_title] => Chelator and use thereof
[patent_app_type] => utility
[patent_app_number] => 15/937428
[patent_app_country] => US
[patent_app_date] => 2018-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 9493
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15937428
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/937428 | Chelator and use thereof | Mar 26, 2018 | Issued |
Array
(
[id] => 17089715
[patent_doc_number] => 11117892
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-14
[patent_title] => Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases
[patent_app_type] => utility
[patent_app_number] => 16/495455
[patent_app_country] => US
[patent_app_date] => 2018-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 24102
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 504
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16495455
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/495455 | Pyrrolo-pyridine derivative compound, method for preparing same, and pharmaceutical composition containing same as active ingredient for prevention or treatment of protein kinase-related diseases | Mar 22, 2018 | Issued |
Array
(
[id] => 17921633
[patent_doc_number] => 11464854
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-11
[patent_title] => Methods and compositions relating to adjuvants
[patent_app_type] => utility
[patent_app_number] => 16/495901
[patent_app_country] => US
[patent_app_date] => 2018-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 88
[patent_figures_cnt] => 90
[patent_no_of_words] => 41992
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 157
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16495901
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/495901 | Methods and compositions relating to adjuvants | Mar 22, 2018 | Issued |
Array
(
[id] => 16735600
[patent_doc_number] => 10961235
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-03-30
[patent_title] => Crystalline form of masitinib
[patent_app_type] => utility
[patent_app_number] => 16/498483
[patent_app_country] => US
[patent_app_date] => 2018-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 10491
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498483
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/498483 | Crystalline form of masitinib | Mar 21, 2018 | Issued |
Array
(
[id] => 15800063
[patent_doc_number] => 20200123174
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-23
[patent_title] => NOVEL PTEFB INHIBITING MACROCYCLIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/498662
[patent_app_country] => US
[patent_app_date] => 2018-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40504
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498662
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/498662 | PTEFb inhibiting macrocyclic compounds | Mar 21, 2018 | Issued |
Array
(
[id] => 15708651
[patent_doc_number] => 20200101091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-02
[patent_title] => ACYLNUCLEOSIDE PHOSPHONATES, PRODRUGS THEREOF AND USE THEREOF AS MEDICAMENT
[patent_app_type] => utility
[patent_app_number] => 16/496888
[patent_app_country] => US
[patent_app_date] => 2018-03-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15432
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 449
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496888
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/496888 | Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament | Mar 20, 2018 | Issued |
Array
(
[id] => 13314605
[patent_doc_number] => 20180208839
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-07-26
[patent_title] => COLOR CONVERSION FILMS COMPRISING A RHODAMINE-BASED FLUORESCENT (RBF) COMPOUND AND PLASMON ENHANCED FLUORESCENT DYES
[patent_app_type] => utility
[patent_app_number] => 15/924302
[patent_app_country] => US
[patent_app_date] => 2018-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18840
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 288
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15924302
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/924302 | COLOR CONVERSION FILMS COMPRISING A RHODAMINE-BASED FLUORESCENT (RBF) COMPOUND AND PLASMON ENHANCED FLUORESCENT DYES | Mar 18, 2018 | Abandoned |
Array
(
[id] => 13335247
[patent_doc_number] => 20180219161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-08-02
[patent_title] => Tetradentate Platinum (II) Complexes Cyclometalated With Functionalized Phenyl Carbene Ligands And Their Analogues
[patent_app_type] => utility
[patent_app_number] => 15/925084
[patent_app_country] => US
[patent_app_date] => 2018-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6605
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 161
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15925084
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/925084 | Tetradentate platinum (II) complexes cyclometalated with functionalized phenyl carbene ligands and their analogues | Mar 18, 2018 | Issued |
Array
(
[id] => 16376290
[patent_doc_number] => 20200325132
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-15
[patent_title] => TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/494570
[patent_app_country] => US
[patent_app_date] => 2018-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26321
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16494570
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/494570 | Tricyclic compounds for use in treatment of proliferative disorders | Mar 15, 2018 | Issued |
Array
(
[id] => 17968217
[patent_doc_number] => 11485731
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-01
[patent_title] => Compounds and methods useful in the treatment of a PRMT5-mediated disorder
[patent_app_type] => utility
[patent_app_number] => 16/494532
[patent_app_country] => US
[patent_app_date] => 2018-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31675
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 532
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16494532
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/494532 | Compounds and methods useful in the treatment of a PRMT5-mediated disorder | Mar 15, 2018 | Issued |
Array
(
[id] => 15363379
[patent_doc_number] => 20200017454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-16
[patent_title] => MACROCYCLIC COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 16/491379
[patent_app_country] => US
[patent_app_date] => 2018-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50063
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -56
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16491379
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/491379 | Macrocyclic compounds | Mar 14, 2018 | Issued |
Array
(
[id] => 18543668
[patent_doc_number] => 11716992
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-08-08
[patent_title] => 5A5B6C tricyclic spirolactone derivative, preparation method therefor and use thereof
[patent_app_type] => utility
[patent_app_number] => 16/755162
[patent_app_country] => US
[patent_app_date] => 2018-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19311
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 79
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16755162
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/755162 | 5A5B6C tricyclic spirolactone derivative, preparation method therefor and use thereof | Mar 13, 2018 | Issued |
Array
(
[id] => 15405333
[patent_doc_number] => 20200022988
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-23
[patent_title] => Fused Pentacyclic Imidazole Derivatives as Modulators of TNF Activity
[patent_app_type] => utility
[patent_app_number] => 16/487988
[patent_app_country] => US
[patent_app_date] => 2018-03-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30523
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487988
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/487988 | Fused pentacyclic imidazole derivatives as modulators of TNF activity | Mar 13, 2018 | Issued |
Array
(
[id] => 17307321
[patent_doc_number] => 11208413
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-28
[patent_title] => Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/492292
[patent_app_country] => US
[patent_app_date] => 2018-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6882
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16492292
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/492292 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | Mar 11, 2018 | Issued |
Array
(
[id] => 17267479
[patent_doc_number] => 11192890
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-12-07
[patent_title] => FGFR kinase inhibitors and pharmaceutical uses
[patent_app_type] => utility
[patent_app_number] => 16/490717
[patent_app_country] => US
[patent_app_date] => 2018-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 22
[patent_no_of_words] => 28682
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 209
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16490717
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/490717 | FGFR kinase inhibitors and pharmaceutical uses | Mar 1, 2018 | Issued |
Array
(
[id] => 15102131
[patent_doc_number] => 10472365
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-11-12
[patent_title] => Short-acting benzodiazepine salts and their polymorphic forms
[patent_app_type] => utility
[patent_app_number] => 15/908081
[patent_app_country] => US
[patent_app_date] => 2018-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 67
[patent_figures_cnt] => 68
[patent_no_of_words] => 16460
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15908081
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/908081 | Short-acting benzodiazepine salts and their polymorphic forms | Feb 27, 2018 | Issued |
Array
(
[id] => 15068567
[patent_doc_number] => 10463749
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-11-05
[patent_title] => Maytansinoid derivatives, conjugates thereof, and methods of use
[patent_app_type] => utility
[patent_app_number] => 15/907142
[patent_app_country] => US
[patent_app_date] => 2018-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 33430
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15907142
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/907142 | Maytansinoid derivatives, conjugates thereof, and methods of use | Feb 26, 2018 | Issued |
Array
(
[id] => 16351879
[patent_doc_number] => 10792372
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-10-06
[patent_title] => Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
[patent_app_type] => utility
[patent_app_number] => 15/906416
[patent_app_country] => US
[patent_app_date] => 2018-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 36
[patent_no_of_words] => 39259
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15906416
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/906416 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | Feb 26, 2018 | Issued |
Array
(
[id] => 13563901
[patent_doc_number] => 20180333498
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2018-11-22
[patent_title] => Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles
[patent_app_type] => utility
[patent_app_number] => 15/894430
[patent_app_country] => US
[patent_app_date] => 2018-02-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 7
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15894430
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/894430 | Phospholipid ether analogs as cancer-targeting drug vehicles | Feb 11, 2018 | Issued |